CD22 and acute lymphoblastic leukemia: Giving confidence in this analysis, many canonical markers were among the strongest hits including BCMA, CD138/SDC1, and CD28 for plasma cells and CD19, CD22, and CD72 for B-ALL cells, respectively (Fig. 1E).